Safety and Efficacy of NOM and OPFS Versus RO for dMMR/MSI-H or POLE-Mutated Gastrointestinal Cancers (NOR-MP)
Safety and Efficacy of Nonoperative Management (NOM) and Organ Preservation First Strategy (OPFS) Versus Radical Operation (RO) for dMMR/MSI-H or POLE-Mutated Gastrointestinal Cancers: A Single-Center, Bidirectional Registry Study
Purpose:
The purpose of this study is to evaluate the safety and efficacy of Non-Operative Management (NOM) and Organ Preservation First Strategy (OPFS) compared with Radical Operation (RO) in patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) or POLE-mutated gastrointestinal cancers.
Background & Design:
With the remarkable efficacy of neoadjuvant immunotherapy in dMMR/MSI-H or POLE-mutated gastrointestinal tumors, organ preservation has become a promising alternative to highly invasive surgeries. The NOR-MP trial is a single-center, bidirectional registry study consisting of two parts: a retrospective cohort study and a prospective observational registry.
Intervention Group (NOM/OPFS): Patients who achieve a clinical complete response (cCR) or near-cCR after neoadjuvant immunotherapy will undergo a "Watch & Wait" (W&W) strategy. Patients with near-cCR or non-cCR who are eligible for organ preservation will undergo local excision (LE) or endoscopic resection (including ESD or EMR).
Comparison Group (Radical Operation): Patients who undergo standard radical surgical resection after neoadjuvant immunotherapy.
The study aims to determine whether an organ-preserving approach can achieve comparable oncological outcomes and safety profiles while significantly improving patients' quality of life compared to radical surgery.
研究概览
详细说明
The NOR-MP trial is a single-center, bidirectional registry study designed to compare the clinical outcomes of Organ Preservation First Strategy (OPFS) / Non-Operative Management (NOM) against standard Radical Operation (RO) for patients diagnosed with dMMR/MSI-H or POLE-mutated gastrointestinal cancers. The study is divided into two sequential parts based on the nature of data collection:
Part 1: Retrospective Cohort Study
This part retrospectively reviews the medical records of eligible patients with dMMR/MSI-H or POLE-mutated gastrointestinal cancers who previously completed neoadjuvant immunotherapy. Patients are allocated into two historical cohorts:
Experimental Cohort (NOM/OPFS): Patients who achieved cCR/near-cCR after neoadjuvant immunotherapy and entered the "Watch & Wait" (W&W) program, as well as those with near-cCR or non-cCR who underwent local excision (LE) or endoscopic resection (including Endoscopic Submucosal Dissection [ESD] or Endoscopic Mucosal Resection [EMR]).
Control Cohort (RO): Patients who underwent radical surgical operation after neoadjuvant immunotherapy. Pathological outcomes (including the proportions of ypCR, ypTisN0, and ypT1-2N0) and surgical safety data will be collected and analyzed.
Part 2: Prospective Registry Study
This part prospectively enrolls newly diagnosed patients with dMMR/MSI-H or POLE-mutated gastrointestinal cancers receiving neoadjuvant immunotherapy. Following treatment evaluation by the multi-disciplinary NOR-MP research team, patients are enrolled into two parallel observational tracks:
Experimental Cohort (NOM/OPFS): Patients eligible for and consenting to NOM or OPFS. This includes the W&W strategy for those achieving cCR/near-cCR, and LE or endoscopic resection (ESD/EMR) for those with near-cCR or non-cCR.
Control Cohort (RO): Patients who proceed to standard radical operation. Pathological response distribution (proportions of ypCR, ypTisN0, ypT1-2N0, and ypT3+ diseases) and short-to-long-term surgical safety endpoints will be prospectively documented.
By comparing the retrospective and prospective cohorts, this study evaluates whether the omission of radical surgery is oncologically safe and preserves organ function without compromising long-term survival.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名：Xiaokang Lei, M.D.
- 电话号码：+8618811181993
- 邮箱：lxkpku@163.com
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Histologically confirmed primary gastrointestinal adenocarcinoma or squamous cell carcinoma (e.g., colorectal cancer, gastric cancer, gastroesophageal junction cancer).
- Confirmed as deficient mismatch repair (dMMR) by immunohistochemistry (IHC), high microsatellite instability (MSI-H) by polymerase chain reaction (PCR) or next-generation sequencing (NGS), or harboring POLE exonuclease domain mutations.
- Received neoadjuvant/conversion immunotherapy (immune checkpoint inhibitors, either monotherapy or combination therapy) prior to treatment response evaluation.
- For the Retrospective Cohort (Part 1): Patients treated between [Start Month/Year] and [End Month/Year] who completed evaluation and subsequent strategy (NOM/OPFS or RO).
- For the Prospective Cohort (Part 2): Newly diagnosed patients who consent to long-term follow-up and multi-disciplinary team (MDT) assessment for organ preservation or radical surgery.
- Age ≥ 18 years at the time of diagnosis.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria:
- Concurrently diagnosed with other active malignant tumors within the past 5 years.
- Patients with proficient mismatch repair (pMMR) / microsatellite stable (MSS) tumors, or wild-type POLE status.
- Evidence of untreatable distant metastasis or systemic disease that precludes local tumor management (NOM/OPFS or radical operation).
- Inability to undergo regular endoscopic, radiological (MRI/CT), or clinical follow-up due to compliance or geographic reasons.
- Refusal to sign the informed consent form (applicable to the prospective cohort).
学习计划
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Experimental Cohort (NOM/OPFS)
Retrospective Cohort Study: Patients who achieved cCR/near-cCR after neoadjuvant immunotherapy and entered the "Watch & Wait" (W&W) program, as well as those with near-cCR or non-cCR who underwent local excision (LE) or endoscopic resection (including Endoscopic Submucosal Dissection [ESD] or Endoscopic Mucosal Resection [EMR]). Prospective Registry Study: Patients eligible for and consenting to NOM or OPFS. This includes the W&W strategy for those achieving cCR/near-cCR, and LE or endoscopic resection (ESD/EMR) for those with near-cCR or non-cCR. |
Patients eligible for and consenting to NOM or OPFS.
This includes the W&W strategy for those achieving cCR/near-cCR, and LE or endoscopic resection (ESD/EMR) for those with near-cCR or non-cCR.
|
|
Control Cohort (RO)
Retrospective Cohort Study: Patients who underwent radical surgical operation after neoadjuvant immunotherapy. Pathological outcomes (including the proportions of ypCR, ypTisN0, and ypT1-2N0) and surgical safety data will be collected and analyzed. Prospective Registry Study: Patients who proceed to standard radical operation. Pathological response distribution (proportions of ypCR, ypTisN0, ypT1-2N0, and ypT3+ diseases) and short-to-long-term surgical safety endpoints will be prospectively documented. |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Organ Preservation Rate (for OPFS/NOM group)
大体时间：Up to 3 years after the completion of neoadjuvant immunotherapy.
|
The percentage of patients in the NOM/OPFS group who successfully maintain their native organ without requiring radical surgical resection or permanent stoma.
|
Up to 3 years after the completion of neoadjuvant immunotherapy.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Surgical Safety and Postoperative Complications
大体时间：Within 30 days and 90 days post-surgery.
|
Incidence and severity of perioperative complications classified by the Clavien-Dindo classification.
This compares the safety data among patients undergoing Radical Operation (RO), Local Excision (LE), or endoscopic resection (ESD/EMR).
|
Within 30 days and 90 days post-surgery.
|
|
Pathological Response Distribution (for RO group)
大体时间：At the time of radical surgery (typically within 4-12 weeks post-immunotherapy).
|
Proportions of patients in the radical operation cohort achieving pathological complete response (ypCR), ypTisN0, ypT1-2N0, and ypT3+ diseases to characterize the pathological efficacy of neoadjuvant immunotherapy.
|
At the time of radical surgery (typically within 4-12 weeks post-immunotherapy).
|
|
Local Regrowth / Recurrence Rate
大体时间：Followed up at regular intervals (every 3-6 months) up to 3 years.
|
Rate of tumor regrowth in patients undergoing the "Watch & Wait" strategy, or local recurrence in patients undergoing local/endoscopic excision.
|
Followed up at regular intervals (every 3-6 months) up to 3 years.
|
|
Overall Survival (OS)
大体时间：Up to 5 years.
|
Defined as the time from treatment initiation to death from any cause.
|
Up to 5 years.
|
|
Disease-Free Survival (DFS) / Disease-Specific Survival (DSS)
大体时间：From enrollment/treatment initiation up to 5 years.
|
To compare the long-term oncological efficacy between the NOM/OPFS group and the RO group.
DFS is defined as the time from the start of neoadjuvant immunotherapy to the date of first documentation of disease recurrence (local, regional, or distant), progression, or death from any cause.
|
From enrollment/treatment initiation up to 5 years.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.